Shares of all four companies rose following the takeover announcement, partly because of the 120 percent premium Pfizer paid over Medivation’s share price before reports of interest earlier this year. Following months of pursuit, Sanofi came up short to Pfizer, which announced a deal Monday to buy San Francisco’s Medivation and its blockbuster cancer...